2 studies found for:    19886987 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Unknown  Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors
Condition: Neuroendocrine Carcinomas
Intervention: Drug: bevacizumab + octreotide LAR + capecitabine
2 Completed 5FU and Octreotide Long-acting Release (LAR) for Neuroendocrine Tumors
Condition: Neuroendocrine Tumors
Intervention: Drug: continuous 5 fluouracil infusion plus long-acting octreotide

Indicates status has not been verified in more than two years